Pygeum / Pygeum africanum for Urinary Symptoms (LUTS)

Verdict: Weak, outdated evidence; guidelines do not recommend

Pygeum africanum shows a modest signal for the urinary symptoms of benign prostatic hyperplasia (BPH), but the evidence is old and methodologically weak. It is not a proven treatment, and modern urology guidelines do not recommend it.

C 🟠 C Weak Evidence Taiwan Regulatory Restriction

🔬Why this grade7-layer evidence engine

The grade rests almost entirely on two systematic reviews that pool the same set of 18 small, short trials (mean ~64 days) in about 1,562 men with BPH (PMID 11099686; PMID 11869585). Pooled, men taking pygeum were roughly twice as likely to report symptom improvement (RR 2.1), with nocturia down about 19%, peak urinary flow up about 23%, and residual urine reduced. The signal is real but low-quality: doses varied widely and the trials did not use validated symptom scales such as the IPSS.

Newer work has not strengthened the case. The 2022 PROFIT cohort (PMID 35435166, n=115) reported an IPSS drop of about 4.5 points, but it had no control group and was industry-funded, so its bias risk is high. A 2023 review of phytotherapy for BPH (PMID 36902686) judged the overall evidence inconclusive and noted that no such agents are recommended in EAU or AUA guidelines. There has been no updated high-quality synthesis.

Regulators and clinicians are split rather than convinced. The WHO monograph supports pygeum for BPH urinary complaints at 100-200 mg/day, but the U.S. FDA grants no approved health claim and European authorities classify it only as 'traditional use,' not established efficacy. Decisively, urology specialty guidance does not recommend phytotherapy for LUTS/BPH, which anchors the weak (Grade C) rating. The data also apply only to BPH-related symptoms, not to urinary symptoms from other causes.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.53
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Taiwan Regulatory Restriction
Confidence
54%
Conflicting evidence
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.25
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
L3 MechanismPlausibility
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.53
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Pygeum africanum for the treatment of patients with BPH: a systematic review and quantitative meta-analysis
PMID: 11099686 2000 系統性回顧 n = 1,562
Finding: Nocturia reduced 19%, peak flow increased 23%, residual urine volume reduced 24%; RR for symptom improvement vs placebo 2.1 (95% CI 1.4–3.1); combined effect size −0.8 SD (95% CI −1.4 to −0.3).
Effect size: RR 2.1 (95% CI 1.4–3.1); SMD −0.8 SD
View on PubMed
Pygeum africanum for benign prostatic hyperplasia (Cochrane systematic review)
PMID: 11869585 2002 系統性回顧 n = 1,562
Finding: Men on Pygeum were >2× more likely to report overall symptom improvement (RR 2.1, 95% CI 1.4–3.1); nocturia −19%, peak flow +23%, residual urine −24%; adverse effects mild and comparable to placebo.
Effect size: RR 2.1 (95% CI 1.4–3.1); nocturia −19%; peak flow +23%
View on PubMed
Effectiveness of Pygeum africanum in patients with LUTS/BPH: a cross-sectional study in real-world clinical practice in Spain (PROFIT Study)
PMID: 35435166 2022 Cohort n = 115
Finding: IPSS decreased mean −4.5 points; QoL impairment (IPSS item 8 ≥4) fell from 45.2% to 22.6% (p<0.001); 60% achieved clinically significant improvement ≥4 IPSS points; no treatment-related AEs.
🟠 Limited quality ⚠️ Industry-funded Effect size: MD −4.5 IPSS points; QoL responders 22.6% vs 45.2% baseline (p<0.001)
View on PubMed
Role of Phytotherapy in the Management of BPH: A Summary of the Literature
PMID: 36902686 2023 系統性回顧
Finding: Phytotherapy evidence for BPH/LUTS is inconclusive overall; Pygeum among agents with modest effectiveness; none currently recommended in EAU/AUA guidelines; all well-tolerated.
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
L4e WHO
Supportive
WHO Monographs on Selected Medicinal Plants, Volume 2 (2002) includes a dedicated monograph: "Cortex Pruni Africanae" (entry 21 of 29 monographs). The monograph covers: definition, synonyms, selected vernacular names, geographical distribution, description, plant material of interest, organoleptic properties, microscopic characteristics, general identity tests, purity tests, chemical assays, ma… source↗
L5c Cleveland Clinic
Cautious
L5e Specialty Society (condition-mapped)
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-urinary-symptoms-INT-pygeum-001 繁體中文版 →